200623-62-7 Usage
Description
N-Fmoc-N'-trityl-D-glutamine, also known as Fmoc-D-Gln(Trt)-OH, is an amino acid derivative characterized by its white to off-white powder form. It plays a significant role in chemical synthesis and peptide chemistry due to its unique structural properties.
Uses
Used in Chemical Synthesis:
N-Fmoc-N'-trityl-D-glutamine is used as a building block for the synthesis of various complex molecules, including pharmaceuticals and bioactive compounds. Its application in this field is attributed to its compatibility with a wide range of chemical reactions and its ability to be easily incorporated into larger molecular structures.
Used in Peptide Chemistry:
In peptide chemistry, N-Fmoc-N'-trityl-D-glutamine serves as a crucial component in the construction of peptide sequences. It is used as a protected amino acid, which aids in the stepwise assembly of peptides while preventing unwanted side reactions. The trityl group provides a stable protection for the amino group, ensuring the selective deprotection and coupling of subsequent amino acids during peptide synthesis.
Used in Pharmaceutical Industry:
N-Fmoc-N'-trityl-D-glutamine is used as a key intermediate in the development of novel drugs and therapeutic agents. Its application in this industry is due to its ability to be modified and incorporated into various drug candidates, potentially leading to the discovery of new treatments for a range of diseases and conditions.
Used in Research and Development:
In the field of research and development, N-Fmoc-N'-trityl-D-glutamine is utilized as a valuable tool for studying the properties and functions of amino acids and peptides. Its use in this context allows scientists to gain a deeper understanding of the molecular mechanisms underlying various biological processes and to develop new strategies for targeting specific biological pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 200623-62-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,6,2 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 200623-62:
(8*2)+(7*0)+(6*0)+(5*6)+(4*2)+(3*3)+(2*6)+(1*2)=77
77 % 10 = 7
So 200623-62-7 is a valid CAS Registry Number.
200623-62-7Relevant articles and documents
Caged xanthones: Potent inhibitors of global predominant MRSA USA300
Chaiyakunvat, Pongkorn,Anantachoke, Natthinee,Reutrakul, Vichai,Jiarpinitnun, Chutima
supporting information, p. 2980 - 2983 (2016/06/13)
Total of 22 caged xanthones were subjected to susceptibility testing of global epidemic MRSA USA300. Natural morellic acid showed the strongest potency (MIC of 12.5 μM). However, its potent toxicity diminishes MRSA therapeutic potential. We synthetically modified natural morellic acid to yield 13 derivatives (3a-3m). Synthetically modified 3b retained strong potency in MRSA growth inhibition, yet the toxicity was 20-fold less than natural morellic acid, permitting the possibility of using caged xanthones for MRSA therapeutic.
NOVEL PEPTIDES DERIVED FROM NCAM (FGLs)
-
, (2011/05/05)
The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.
GLP-2 compounds, formulations, and uses thereof
-
, (2008/06/13)
The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
